[ad_1] Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss, however, due to charges associated with the company’s acquisition of Prometheus Biosciences earlier this year. Merck swung to a net loss of $5.98 billion, or…
[ad_1] Pavlo Gonchar | Lightrocket | Getty Images Pfizer on Tuesday reported second-quarter adjusted earnings that topped Wall Street’s expectations, but posted revenue that fell short of estimates as Covid product sales plunged. Pfizer reported second-quarter sales of $12.73 billion, down 54% from the same period a year ago. The company’s Covid vaccine raked in…
[ad_1] We’re taking a hard look at the Bullpen and the rest of the market for new opportunities. [ad_2] Source link
[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved Alzheimer’s drug Leqembi. It’s the latest round of layoffs after Biogen slashed nearly 900…
[ad_1] Kenvue, a unit of Johnson & Johnson’s consumer health business. CFOTO | Future Publishing | Getty Images Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer….
[ad_1] Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, speaks during an interview to celebrate its IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan Mcdermid | Reuters Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for…
[ad_1] Johnson & Johnson (JNJ) reported strong second – quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. J & J’s second-quarter reported sales rose 6.3% year-over-year to $25.53 billion, exceeding the Refinitv consensus estimate of $24.63 billion. (On an…
[ad_1] Kenvue shares fell on Thursday even though the consumer health company beat second-quarter revenue and earnings expectations in the its first quarterly report since it spun out from Johnson & Johnson two months ago. The company, formerly J&J’s consumer health division, also issued an upbeat sales outlook for 2023. But Kenvue CEO Thibaut Mongon noted during an earnings call…
[ad_1] Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations, and lifted its full-year guidance as sales from the company’s medtech business jumped. The medtech division provides devices for surgeries, orthopedics and vision. The company is benefitting from a rebound in demand for non-urgent surgeries among older adults,…
[ad_1] Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Bloomberg | Bloomberg | Getty Images Novartis shares jumped on Tuesday after the Swiss drugmaker raised its full-year guidance on strong drug sales and announced a $15 billion share buyback. The…
